Selinexor plus ruxolitinib showed greater spleen reductions and an early survival signal in JAK-naive myelofibrosis, Claire Harrison, MD, explained.
Claire Harrison, MD
Advertisement
Claire Harrison, MD, is a professor of hematology at the Guy's and St. Thomas' NHS Foundation Trust in London, England.
Articles by Claire Harrison, MD
Late-breaking phase 3 SENTRY data show selinexor plus ruxolitinib improves spleen volume, survival, and disease markers in myelofibrosis.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 May Follow a Different Seasonal Pattern Than Influenza, RSV
2
Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure
3
Real-World Data Show MASH Progresses Faster Than Trials Suggest
4
Sarcoma's Rarity Limits Trials and Biomarker-Driven Treatment Options: Alexander Spira, MD, PhD, FACP, FASCO
5